Creo Medical (AIM: CREO)

Last close As at 20/12/2024

GBP0.17

0.75 (4.62%)

Market capitalisation

GBP71m

UK-based Creo Medical focuses on the development and commercialisation of minimally invasive electrosurgical devices. Its six products in the flagship CROMA platform have all been CE marked, with five cleared by the FDA. Acquired in 2020, Albyn Medical provides Creo with profitable products and a direct salesforce in Europe.

Latest Insights

View More

Healthcare | Flash note

Creo Medical — Consumables business divested in strategic move

Healthcare | Flash note

Creo Medical — Intuitive deal expansion is a notable milestone

Healthcare | edison tv

Creo Medical – executive interview with Craig Gulliford, CEO

Healthcare | Update

Creo Medical — Setting the stage for pivotal growth

creo05

Sector

Healthcare

Equity Analyst

Arron Aatkar

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Craig Gulliford

    CEO

  • David Woods

    Chief commercial officer

  • Richard Rees

    CFO

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free